story of the week
Molecularly Guided Therapy vs Chemotherapy After Disease Control in Unfavourable Cancer of Unknown Primary
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
Lancet 2024 Aug 10;404(10452)527-539, A Krämer, T Bochtler, C Pauli, KK Shiu, N Cook, JJ de Menezes, RA Pazo-Cid, F Losa, DG Robbrecht, J Tomášek, C Arslan, M Özgüroğlu, M Stahl, F Bigot, SY Kim, Y Naito, A Italiano, N Chalabi, G Durán-Pacheco, C Michaud, J Scarato, M Thomas, JS Ross, H Moch, L MileshkinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.